ROWC yields 500000.00% · ABBV yields 3.06%● Live data
📍 ROWC pulled ahead of the other in Year 1
Combined, ROWC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ROWC + ABBV for your $10,000?
The Rowe Companies, Inc. is a holding company, which through its subsidiaries manufactures and markets home furnishings in the United States. The company operates in two segments, Wholesale Home Furnishings and Retail Home Furnishings. The Wholesale Home Furnishings segment designs and manufactures upholstered furniture, including sofas, loveseats, benches, ottomans and chairs, occasional chairs, and sleep sofas covered with fabric, as well as finished leather accent pieces, such as chairs, benches, and ottomans. The Retail Home Furnishings segment offers upholstered furniture, leather furniture, case goods, dining sets, rugs, and home accessories through company-owned stores, catalog, and Internet. The Rowe Companies, Inc. was formerly known as Rowe Furniture Corporation and changed its name to The Rowe Companies, Inc. in March 1999. The Rowe Companies, Inc. was founded in 1946 and is based in McLean, Virginia. On September 18, 2006, The Rowe Companies, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Eastern District of Virginia, Alexandria. The plan was later approved as Chapter 11 liquidation October 25, 2007.
Full ROWC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.